SUBSTANCE: invention relates to compounds of the general formula (I) α where one of X and Y means C= O and another means C= O or among CH2 one means R1, R2, R3, R4 and others mean hydrogen atom; -NHR5 mean hydrogen atom or alkyl under condition that R5, R6 is not hydrogen atom if X and Y are C= O and one of R6 means amino-group. New compounds of the formula (I) show property to inhibit tumor necrosis factor R1, R2, R3, R4 and therefore they can be used in pharmaceutical composition as an active component. Also, compounds of the formula (I) can be used in method for decrease of unfavorable levels of tumor necrosis factor-α in mammals.
EFFECT: valuable medicinal properties of compounds and composition.
8 cl, 1 tbl, 37 ex.
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED 2,6-DIOXOPIPERIDINES, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF DECREASE OF TUMOR NECROSIS FACTOR- LEVEL | 1997 |
|
RU2177944C2 |
| 2,6-DIOXOPIPERIDINE, METHOD FOR REDUCTION OF UNDESIRABLE LEVELS OF TNF-ALPHA IN MAMMAL, PHARMACEUTICAL COMPOSITION | 1998 |
|
RU2209207C2 |
| DERIVATIVES OF 2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE, THEIR SYNTHESIS AND APPLICATION AS INHIBITORS OF INFLAMMATORY CYTOKINES | 1999 |
|
RU2200159C2 |
| METHOD OF PRODUCING LENALIDOMIDE AND AN INTERMEDIATE FOR PRODUCTION THEREOF | 2020 |
|
RU2730858C1 |
| ISOINDOLINE COMPOUND, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND THEIR USE | 2019 |
|
RU2813232C2 |
| CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM | 2018 |
|
RU2795146C2 |
| ISOINDOLINE COMPOUNDS USED FOR TREATING CANCER | 2009 |
|
RU2527952C2 |
| ARYLMETHOXY ISOINDOLIN DERIVATIVE, COMPOSITIONS INCLUDING THEREOF AND METHODS OF THEIR APPLICATION | 2011 |
|
RU2567753C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
